Area of research
Pulmonary and Respiratory Medicine · Cancer Research
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Prostate Cancer Treatment and Research, and Fibroblast Growth Factor Research.
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Saturation mutagenesis identifies activating and resistance-inducing FGFR kinase domain mutations
<i>BRAF</i> Kinase Domain Duplication as a Potential On-Target Resistance Mechanism After Dabrafenib-Trametinib Therapy in a Patient With <i>BRAF</i><sup>V600E</sup>-Mutated Lung Adenocarcinoma.
Supplementary Table 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Figure 4 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S10 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S3 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S12 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S8 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S13 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 1 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Table S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S5 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S4 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 2 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S14 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Data from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Table 3 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S6 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Data S2 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Tables S1-S11 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Supplementary Table 1 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Supplementary Data S7 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure S3 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figures S1-S24 from Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Supplementary Methods S1 from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors
Supplementary Figure 5 from Resistance to Selective FGFR Inhibitors in <i>FGFR-</i>Driven Urothelial Cancer
Data from Genomic Profiling of Metastatic Castration-Resistant Prostate Cancer Samples Resistant to Androgen Receptor Pathway Inhibitors